Open-label versus double-blind placebo treatment in irritable bowel syndrome: study protocol for a randomized controlled trial
作者: Sarah BallouTed J. KaptchukWilliam HirschJudy NeeJohanna IturrinoKathryn T. HallJohn M. KelleyVivian ChengIrving KirschEric JacobsonLisa ConboyAnthony LemboRoger B. Davis
作者单位: 1Division of Gastroenterology, Beth Israel Deaconess Medical Center
2Beth Israel Deaconess Medical Center/Harvard Medical School
3Department of Global Health and Social Medicine Harvard Medical School
4Brigham and Women’s Hospital/Harvard Medical School
5Endicott College
6Beth Israel Deaconess Medical Center
7Beth Israel Deaconess Medical Center/Harvard Medical Schoo
刊名: Trials, 2017, Vol.18 (1)
来源数据库: Springer Nature Journal
DOI: 10.1186/s13063-017-1964-x
关键词: Placebo effectsOpen-label placeboIrritable bowel syndromeResearch methodsMulti-disciplinary modelsPeppermint oil
英文摘要: Placebo medications, by definition, are composed of inactive ingredients that have no physiological effect on symptoms. Nonetheless, administration of placebo in randomized controlled trials (RCTs) and in clinical settings has been demonstrated to have significant impact on many physical and psychological complaints. Until recently, conventional wisdom has suggested that patients must believe that placebo pills actually contain (or, at least, might possibly contain) active medication in order to elicit a response to placebo. However, several recent RCTs, including patients with irritable bowel syndrome (IBS), chronic low back pain, and episodic migraine, have demonstrated that individuals receiving open-label placebo (OLP) can still experience symptomatic improvement and benefit from...
原始语种摘要: Placebo medications, by definition, are composed of inactive ingredients that have no physiological effect on symptoms. Nonetheless, administration of placebo in randomized controlled trials (RCTs) and in clinical settings has been demonstrated to have significant impact on many physical and psychological complaints. Until recently, conventional wisdom has suggested that patients must believe that placebo pills actually contain (or, at least, might possibly contain) active medication in order to elicit a response to placebo. However, several recent RCTs, including patients with irritable bowel syndrome (IBS), chronic low back pain, and episodic migraine, have demonstrated that individuals receiving open-label placebo (OLP) can still experience symptomatic improvement and benefit from...
全文获取路径: Springer Nature  (合作)
分享到:
来源刊物:
影响因子:2.206 (2012)

×
关键词翻译
关键词翻译
  • label 标签标记
  • irritable 易发怒的
  • placebo 无效对照药
  • demonstrated 探明的储量
  • inactive 不活泼的
  • bowel 
  • recent 近来的
  • controlled 受控
  • treatment 处理
  • several 各自